Search Within

Michael Morris

  1. "Society of Nuclear Medicine"
Formats
  1. Journal Article (24)
  2. Meeting Abstract (14)
  3. Review (4)
  4. Editorial (1)
  5. Guidelines (1)
  6. Miscellaneous (1)
Groups
  1. Department of Medicine (45)
  2. Genitourinary Oncology Service (45)
  3. Solid Tumor Oncology Division (45)
  4. Radiology, Department of (32)
  5. Molecular Imaging and Therapy Service (29)
  6. GSK Faculty (24)

More Groups

People
  1. Steven Larson (18)
  2. Howard Scher (14)
  3. John Humm (12)
  4. Neeta Pandit-Taskar (11)
  5. Jason Lewis (8)
  6. Bradley Beattie (7)

More People

Years
  1. 2025 (2)
  2. 2024 (5)
  3. 2023 (2)
  4. 2022 (3)
  5. 2021 (2)
  6. 2020 (2)

More Years

Publications
  1. Journal of Nuclear Medicine (45)
Publishers
  1. Society of Nuclear Medicine (45)

Results (45)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CONVERGE-01: Dosimetry, randomized dose optimization, dose escalation and efficacy of Ac-225 rosopatamab tetraxetan in participants with PSMA-positive castration-resistant prostate cancer
    Meeting Abstract

    Pandit-taskar, N.; Morris, M.; Kiess, A.; Nordquist, L.; Gupta, S.; George, D.; Antonarakis, E.; Messmann, R.; Kantoff, P.; Vallabhajosula, S.; more...
    Journal of Nuclear Medicine (2025)

    Fulltext@MSK | Save
  • Symptomatic prostate-specific membrane antigen PET–positive radionecrosis after multimodality brain metastasis–directed treatment including [(177)Lu]Lu-PSMA-617
    Journal Article

    Imber, B. S.; Yu, K. K. H.; Abida, W.; Pike, L. R. G.; Grkovski, M.; Kaley, T. J.; Morris, M. J.; Bodei, L.; Nosov, A.; Dunphy, M. P. S.; more...
    Journal of Nuclear Medicine (2025)

    Fulltext@MSK | Save
  • Phase 3 trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)
    Meeting Abstract

    Herrmann, K.; Sartor, O.; Castellano, D.; de Bono, J.; Shore, N.; Chi, K.; Crosby, M.; Piulats, J.; Flechon, A.; Wei, X.; more...
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Standardized template for clinical reporting PSMA PET/CT scans
    Meeting Abstract

    Esfahani, S.; Morris, M.; Sartor, O.; Frydenberg, M.; Fanti, S.; Calais, J.; Vapiwala, N.
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Best patient care practices for administering PSMA-targeted radiopharmaceutical therapy
    Review

    Calais, J.; Morris, M. J.; Kendi, A. T.; Kalebasty, A. R.; Tutrone, R.; Anderson, M. J.; Sartor, O.
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • A phase 0 study to assess the biodistribution and pharmacokinetics of a radiolabeled antibody targeting human kallikrein 2 in participants with metastatic castration-resistant prostate cancer
    Journal Article

    Pandit-Taskar, N.; O'Donoghue, J. A.; Chetty, D.; Max, S.; Wanik, D.; Ilovich, O.; Russell, M.; Nyima, T.; Divgi, C. R.; Yu, M.; more...
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Design considerations in the PSMAfore trial
    Editorial

    Sartor, O.; Fizazi, K.; Herrmann, K.; Morris, M. J.
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • SNMMI consensus statement on patient selection and appropriate use of (177)Lu-PSMA-617 radionuclide therapy
    Guidelines

    Hope, T. A.; Antonarakis, E. S.; Bodei, L.; Calais, J.; Iravani, A.; Jacene, H.; Koo, P. J.; Morgans, A. K.; Osborne, J. R.; Tagawa, S. T.; more...
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • Looking at the future of prostate cancer treatment: A conversation between Michael Morris, Jeremie Calais, and Johannes Czernin
    Miscellaneous

    Morris, M. J.; Calais, J.; Czernin, J.
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • From concept to regulatory drug approval: Lessons for theranostics
    Review

    Perera, M.; Morris, M. J.
    Journal of Nuclear Medicine (2022)

    Fulltext@MSK | Save